

Figure S1. OxATP inhibits body edema in *pkd2* morphants at 5 dpf. (A) A wild type sibling at 5 dpf (lateral view, anterior to the left). (B) Abdominal edema (arrowhead) in a *pkd2* morphant at 5 dpf. (C) Abdominal edema (arrowhead) in a *pkd2* morphant treated with 100uM BzATP. (D) No visible edema in a *pkd2* morphant treated with 100uM OxATP. (E) The frequencies of edematous phenotype in *pkd2* morphants treated with BzATP (n=81) and OxATP (n=87) as compared with untreated controls (n=82). * P < 0.01 from three independent experiments.




Figure S2. Comparative expression of IL-1 mRNA by RT-PCR in *pkd2* morphants at 5 dpf. Embryos were treated with 100 μ M BzATP or 100 μ M OxATP for 5 days. n=6 from four separate experiments. * indicates significant different means compared with the controls with $P < 0.05$ by Kruskal-Wallis test and Dunn's Multiple Comparison Test.